Vinorelbine and Prednisone in older Cancer Patients with Hormone-Refractory Metastatic Prostate Cancer a Phase II Study
Authors:
- 1 January 2003
- journal article
- research article
- Published by SAGE Publications in Tumori Journal
- Vol. 89 (1) , 26-30
Abstract
Aims and Background: Prostate cancer is a common disease in older men. Since it is hormone resistant, no treatment may improve survival. In patients with hormone-refractory prostate cancer, clinical benefit is an important treatment end point. Study Design: This study evaluated the efficacy and toxicity of a vinorelbine and prednisone combination in hormone-refractory prostate cancer patients. Vinorelbine was administered at the dose of 25 mg/m2 on days 1 and 8, every three weeks; prednisone was administered orally at the dose of 12 mg/day. Thirty consecutive patients, 65 years or older, with progressive (PSA increase or increase in bidimensionally measurable lesion) metastatic prostate adenocarcinoma were enrolled. Four patients (13%) had a partial response and 14 (46%) stable disease. Time to progression for the entire group was 4.5 months (range, 2–13) and 7.5 months for the group of responders (range, 3–13). A PSA decrease >50% was registered in 36% of the patients. Pain reduction was recorded in 44.4% of the patients and stability in 14.8%. Results: The treatment was well tolerated and grade 3 toxicity was found in 2 cases of anemia and 2 cases of leukopenia without fever. Conclusions: The schedule is able to control the evolution of hormone-refractory prostate cancer and to give a clinical benefit. These results provide information for further clinical trials in a large series of elderly cancer patients.Keywords
This publication has 30 references indexed in Scilit:
- Increased transcriptional activity of prostate-specific antigen in the presence of TNP-470, an angiogenesis inhibitorBritish Journal of Cancer, 1999
- Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancerEuropean Journal of Cancer, 1997
- Vinorelbine (Navelbiner`): A Third-Generation Vinca AlkaloidCancer Investigation, 1997
- Cancer statistics, 1997CA: A Cancer Journal for Clinicians, 1997
- Suramin-Induced Decrease in Prostate-Specific Antigen Expression With No Effect on Tumor Growth in the LNCaP Model of Human Prostate CancerJNCI: Journal of the National Cancer Institute, 1996
- Vinorelbine: an overviewCancer Treatment Reviews, 1996
- Lack of Correlation Between Prostate-Specific Antigen and the Presence of Measurable Soft Tissue Metastases in Hormone-Refractory Prostate CancerCancer Investigation, 1996
- Management of Cancer of the ProstateNew England Journal of Medicine, 1994
- The McGill Pain Questionnaire: Major properties and scoring methodsPain, 1975
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958